PURPOSE: Prolonged latency of visual evoked potentials (VEP) has been used to identify clinically silent lesions in multiple sclerosis (MS) suspects. The objective of this study was to determine the reliability of VEP to predict the development of MS in MS suspects. METHODS: Retrospective hospital records of MS suspects were evaluated. VEP was analyzed together with subsequent diagnostic confirmation of MS by McDonald diagnostic criteria for MS-2005. RESULTS: MS developed in 12 of 35 patients (34 %) and 23 (66 %) failed to exhibit diagnostic characteristics. P100 latencies and interocular latency differences were longer in clinically definite multiple sclerosis (CDMS) than non-CDMS patients (p = 0.002, 0.001, respectively). All patients in the subsequent MS group had P100 latencies longer than102 ms, a mean of our MS-free subjects thus providing 100 % of sensitivity. No patient developed MS with a P100 latency <102 ms. Brain MRI lesions associated significantly with developing CDMS (p = 0.001). Predictability of developing CDMS was highest when criteria for P100 latency, interocular latency difference, and brain MRI lesions were combined. CONCLUSION: MS suspects with a P100 latency longer than mean of MS-free subjects are more likely to develop MS than those with lower values. VEP latency combined with MRI could improve the accuracy of MS prediction.
PURPOSE: Prolonged latency of visual evoked potentials (VEP) has been used to identify clinically silent lesions in multiple sclerosis (MS) suspects. The objective of this study was to determine the reliability of VEP to predict the development of MS in MS suspects. METHODS: Retrospective hospital records of MS suspects were evaluated. VEP was analyzed together with subsequent diagnostic confirmation of MS by McDonald diagnostic criteria for MS-2005. RESULTS: MS developed in 12 of 35 patients (34 %) and 23 (66 %) failed to exhibit diagnostic characteristics. P100 latencies and interocular latency differences were longer in clinically definite multiple sclerosis (CDMS) than non-CDMSpatients (p = 0.002, 0.001, respectively). All patients in the subsequent MS group had P100 latencies longer than102 ms, a mean of our MS-free subjects thus providing 100 % of sensitivity. No patient developed MS with a P100 latency <102 ms. Brain MRI lesions associated significantly with developing CDMS (p = 0.001). Predictability of developing CDMS was highest when criteria for P100 latency, interocular latency difference, and brain MRI lesions were combined. CONCLUSION: MS suspects with a P100 latency longer than mean of MS-free subjects are more likely to develop MS than those with lower values. VEP latency combined with MRI could improve the accuracy of MS prediction.
Authors: D W Paty; J J Oger; L F Kastrukoff; S A Hashimoto; J P Hooge; A A Eisen; K A Eisen; S J Purves; M D Low; V Brandejs Journal: Neurology Date: 1988-02 Impact factor: 9.910
Authors: Larissa K Grover; Donald C Hood; Quraish Ghadiali; Tomas M Grippo; Adam S Wenick; Vivienne C Greenstein; Myles M Behrens; Jeffrey G Odel Journal: Doc Ophthalmol Date: 2008-01-18 Impact factor: 2.379
Authors: G Filippini; G C Comi; V Cosi; L Bevilacqua; M Ferrarini; V Martinelli; R Bergamaschi; M Filippi; A Citterio; L D'Incerti Journal: J Neurol Date: 1994-01 Impact factor: 4.849
Authors: Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2005-12 Impact factor: 10.422
Authors: Philipp Schwenkenbecher; Anastasia Sarikidi; Lena Bönig; Ulrich Wurster; Paul Bronzlik; Kurt-Wolfram Sühs; Refik Pul; Martin Stangel; Thomas Skripuletz Journal: Int J Mol Sci Date: 2017-09-27 Impact factor: 5.923
Authors: M Satue; L Jarauta; J Obis; M Cipres; M J Rodrigo; C Almarcegui; I Dolz; J R Ara; J Martin; L E Pablo; E Garcia-Martin Journal: J Ophthalmol Date: 2019-09-18 Impact factor: 1.909
Authors: James V M Hanson; Mei-Yee Ng; Helen K Hayward-Koennecke; Sven Schippling; Kelly A Reeve; Christina Gerth-Kahlert Journal: Doc Ophthalmol Date: 2021-10-27 Impact factor: 2.379
Authors: Riwanti Estiasari; Adisresti Diwyacitta; Muhammad Sidik; Ni Nengah Rida Ariarini; Freddy Sitorus; Saraf Shafa Marwadhani; Kartika Maharani; Darma Imran; Reza Aditya Arpandy; David Pangeran; Manfaluthy Hakim Journal: Neurol Res Int Date: 2021-06-17